Reported covered position: Leg. Dir, Rep. Nydia M. Velazquez, Nov 2019-March 2022;Sr Leg Asst, Rep. Nydia M. Velazquez, May 2017-Nov 2019;Leg Asst, October 2016-April 2017; Staff Asst, May 2014-Sept 2016 Comm on Small Business, Leg Dir, Oct 1, 2021-March 15, 2022
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2026 · third_quarter · Q3
Monitor and review of issues related to the Section 301 tariffs; Monitor and review of issues related to the Section 232 tariffs; Monitor and review of issues related to the U.S.-China Board of Trade General monitoring and review of Executive Order 14257 and impacts on OTC products; General monitoring and review of legislative and executive actions on international trade policy related to tariffs, import/export concerns; General monitoring of legislative and administrative action related to review of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
Source: Senate LDA
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
Oral Health Products Inclusion Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information. H.R. 6832 PACK Act (Packaging and Claims Knowledge Act)
ACCESS Through OTC Innovation Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
ACCESS Through OTC Innovation Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
ACCESS Through OTC Innovation Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Dietary Supplement Regulatory Uniformity Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Dietary Supplement Regulatory Uniformity Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Recycled Materials Attribution Act of 2026
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications, specifically as it relates to additional domestic production of healthcare products; General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities. H.R. 7502 Recycled Materials Attribution Act (RMAA)
Recycled Materials Attribution Act of 2026
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings. H.R. 7502 Recycled Materials Attribution Act (RMAA)
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Dietary Supplement Listing Act of 2026
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Dietary Supplement Listing Act of 2026
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Dietary Supplement Listing Act of 2026
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
Over-the-Counter Monograph Drug User Fee Amendments
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Over-the-Counter Monograph Drug User Fee Amendments
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments.
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments.
ACCESS Through OTC Innovation Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Over-the-Counter Monograph Drug User Fee Amendments
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Over-the-Counter Monograph Drug User Fee Amendments
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.
OTC Monograph Drug User Fee Transparency Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
OTC Monograph Drug User Fee Transparency Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Infrastructure Investment and Jobs Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of issues related to federal tax amortization of research and development expenses; General review and monitoring of issues that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of issues and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; Continued monitor and review of fiscal year (FY) 2025 budget resolution in both House and Senate, along with associated reconciliation instructions.
General monitoring of legislative and administrative action related to climate change; and General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings; and H.R. 2964/S.1350 Wastewater Infrastructure Pollution Prevention and Environmental Safety Act/WIPPES Act
General monitoring of legislative and administrative action related to climate change; and General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings; and H.R. 2964/S.1350 Wastewater Infrastructure Pollution Prevention and Environmental Safety Act/WIPPES Act
Training and Nutrition Stability
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General review and monitoring of farm bill legislation, particularly provisions related to nutrition; General review and monitoring of legislative and administrative action related to White House Conference on Hunger; and H.R.3087 - Training and Nutrition Stability
Training and Nutrition Stability
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General review and monitoring of farm bill legislation, particularly provisions related to nutrition; General review and monitoring of legislative and administrative action related to White House Conference on Hunger; H.R.3087 - Training and Nutrition Stability; and General review and monitoring legislative actions related to the Farm Bill.
Training and Nutrition Stability
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General review and monitoring of farm bill legislation, particularly provisions related to nutrition; General review and monitoring of legislative and administrative action related to White House Conference on Hunger; and H.R.3087 - Training and Nutrition Stability
Medicare Dental Benefit Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Medicare Dental Benefit Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Medicare Dental Benefit Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Medicare Dental Benefit Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
Improving Measurements for Loneliness and Isolation Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 6284 Improving Measurements for Loneliness and Isolation Act General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.
Improving Measurements for Loneliness and Isolation Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 6284 Improving Measurements for Loneliness and Isolation Act General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.
Improving Measurements for Loneliness and Isolation Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Measurements for Loneliness and Isolation Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Measurements for Loneliness and Isolation Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 6284 Improving Measurements for Loneliness and Isolation Act General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.
Improving Measurements for Loneliness and Isolation Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Measurements for Loneliness and Isolation Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 6284 Improving Measurements for Loneliness and Isolation Act General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.
Improving Measurements for Loneliness and Isolation Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Tax Relief for American Families and Workers Act of 2024
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
Tax Relief for American Families and Workers Act of 2024
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
Tax Relief for American Families and Workers Act of 2024
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
Tax Relief for American Families and Workers Act of 2024
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R.8070, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; and General review and monitoring of nutrition and dietary supplement trends with U.S. military.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R.8070, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; and General review and monitoring of nutrition and dietary supplement trends with U.S. military.
Medicare Medically Necessary Dental Care Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Medicare Medically Necessary Dental Care Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Medicare Medically Necessary Dental Care Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Medicare Medically Necessary Dental Care Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Oral Health Literacy and Awareness Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
General monitoring of legislative and administrative action related to climate change; and General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings; and H.R. 2964/S.1350 Wastewater Infrastructure Pollution Prevention and Environmental Safety Act/WIPPES Act
General monitoring of legislative and administrative action related to climate change; and General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings; and H.R. 2964/S.1350 Wastewater Infrastructure Pollution Prevention and Environmental Safety Act/WIPPES Act
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Improving Whole Health for Veterans with Chronic Conditions Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
Medicare Dental Benefit Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Medicare Dental Benefit Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Medicare Dental Benefit Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Medicare Dental Benefit Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
SUPPORT for Patients and Communities Reauthorization Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
SUPPORT for Patients and Communities Reauthorization Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
SUPPORT for Patients and Communities Reauthorization Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
SUPPORT for Patients and Communities Reauthorization Act
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Oral Health Literacy and Awareness Act of 2023
Client: HALEON US HOLDINGS LLC · Firm: HALEON US HOLDINGS LLC
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; General review and monitoring of implementation of One Big Beautiful Bill Act (OBBBA)
General review of legislative and administration action related to pediatric over-the-counter medication concerns.
General review and monitoring of processes impacting over-the-counter switches. General review and monitoring of legislation impacting labeling requirements.
General review and monitoring of U.S. diplomatic relations.
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H.R. 1219, Oral Health Products Inclusion Act S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
General review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers.
General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information. H.R. 6832 PACK Act (Packaging and Claims Knowledge Act)
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications, specifically as it relates to additional domestic production of healthcare products; General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities. H.R. 7502 Recycled Materials Attribution Act (RMAA)
General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings. H.R. 7502 Recycled Materials Attribution Act (RMAA)
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
General monitoring of issues and administrative action related to intellectual property protection.
General monitoring and review of issues and executive actions related to or impacting multivitamins and nutrition; including GRAS standards.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2026 · second_quarter · Q2
General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
General review of legislative and administration action related to pediatric over-the-counter medication concerns.
General review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers.
General monitoring and review of issues and executive actions related to or impacting multivitamins and nutrition; including GRAS standards.
General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; General review and monitoring of implementation of One Big Beautiful Bill Act (OBBBA)
General review and monitoring of processes impacting over-the-counter switches. General review and monitoring of legislation impacting labeling requirements.
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
General review and monitoring of U.S. diplomatic relations.
Monitor and review of issues related to the Section 301 tariffs; Monitor and review of issues related to the Section 232 tariffs; Monitor and review of issues related to reciprocal tariffs under International Economic Emergency Powers Act; General monitoring and review of Executive Order 14257 and impacts on OTC products; General monitoring and review of legislative and executive actions on international trade policy related to tariffs, import/export concerns; General monitoring of legislative and administrative action related to review of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information.
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications, specifically as it relates to additional domestic production of healthcare products; General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities.
General monitoring of issues and administrative action related to intellectual property protection.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2026 · first_quarter · Q1
General review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers.
General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information.
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
General review of legislative and administration action related to pediatric over-the-counter medication concerns.
General review and monitoring of processes impacting over-the-counter switches.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; General review and monitoring of implementation of One Big Beautiful Bill Act (OBBBA)
Monitor and review of issues related to the Section 301 tariffs; Monitor and review of issues related to the Section 232 tariffs; Monitor and review of issues related to reciprocal tariffs under International Economic Emergency Powers Act; General monitoring and review of Executive Order 14257 and impacts on OTC products; General monitoring and review of legislative and executive actions on international trade policy related to tariffs, import/export concerns; General monitoring of legislative and administrative action related to review of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings.
General monitoring and review of issues and executive actions related to or impacting multivitamins and nutrition.
General review and monitoring of U.S. diplomatic relations.
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications, specifically as it relates to additional domestic production of healthcare products; General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities.
General monitoring of issues and administrative action related to intellectual property protection.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2025 · fourth_quarter · Q4
General review and monitoring of U.S. diplomatic relations.
General review and monitoring of the National Defense Authorization Act (NDAA).
General review of legislative and administration action related to pediatric over-the-counter medication concerns.
General review and monitoring of processes impacting over-the-counter switches.
General review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers.
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications, specifically as it relates to additional domestic production of healthcare products; General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities.
General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings.
H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments.
General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information.
General monitoring of issues and administrative action related to intellectual property protection.
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for supporting certain administrative order requests with respect to over-the-counter monograph drugs, and for other purposes. S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; General review and monitoring of implementation of One Big Beautiful Bill Act (OBBBA)
Monitor and review of issues related to the Section 301 tariffs; Monitor and review of issues related to the Section 232 tariffs; Monitor and review of issues related to reciprocal tariffs under International Economic Emergency Powers Act; General monitoring and review of Executive Order 14257 and impacts on OTC products; General monitoring and review of legislative and executive actions on international trade policy related to tariffs, import/export concerns; General monitoring of legislative and administrative action related to review of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
General monitoring and review of issues and executive actions related to or impacting multivitamins and nutrition.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2025 · third_quarter · Q3
General review of issues and administration action related to pediatric over-the-counter medication concerns.
General review and monitoring of processes impacting over-the-counter switches.
General monitoring and review of issues and executive actions related to or impacting multivitamins and nutrition.
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications, specifically as it relates to additional domestic production of healthcare products; General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities.
General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings.
General review and monitoring of U.S. diplomatic relations.
General review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers.
H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments.
General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information.
General monitoring of issues and administrative action related to intellectual property protection.
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); H R.5371 - Continuing Appropriations and Extensions Act, 2026, in particular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; General review and monitoring of implementation of One Big Beautiful Bill Act (OBBBA)
Monitor and review of issues related to the Section 301 tariffs; Monitor and review of issues related to the Section 232 tariffs; Monitor and review of issues related to reciprocal tariffs under International Economic Emergency Powers Act; General monitoring and review of Executive Order 14257 and impacts on OTC products; General monitoring and review of legislative and executive actions on international trade policy related to tariffs, import/export concerns; General monitoring of legislative and administrative action related to review of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2025 · second_quarter · Q2
General monitoring of issues and administrative action related to intellectual property protection.
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Review of issues impacting the Dietary Supplement Health and Education Act of 1994; General review of issues and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2025 · first_quarter · Q1
General monitoring and review of issues and executive actions related to or impacting multivitamins and nutrition.
General review of federal policies applying towards paid family and medical leave; and General review of issues and administration action related to pediatric over-the-counter medication concerns.
General monitoring and review of legislative and executive actions on international trade policy related to tariffs, import/export concerns; General monitoring of legislative and administrative action related to review of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2024 · third_quarter · RA
Issues related to consumer health care
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2024 · fourth_quarter · Q4
General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; and Monitor legislative and administrative action related to pseudoephedrine regulation.
General monitoring of legislative and administrative action related to intellectual property protection.
General review of federal policies applying towards paid family and medical leave.
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2024 · third_quarter · Q3
H.R.8070, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; and General review and monitoring of nutrition and dietary supplement trends with U.S. military.
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2024 · fourth_quarter · RA
Issues related to consumer health care
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2024 · second_quarter · Q2
General review of federal policies applying towards paid family and medical leave.
H.R.8070, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; and General review and monitoring of nutrition and dietary supplement trends with U.S. military.
H.R. 6284 Improving Measurements for Loneliness and Isolation Act General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2024 · first_quarter · Q1
General review and monitoring of renewable energy legislation and regulations.
Multivitamin and nutrition issues. Review of legislative or administrative action related to melatonin, specifically gummy products on products labeled for adult use; and S Res 35 Resolution designating October 22 through October 28, 2023, as "Natural Product Industry Week"
General review of FDA rulemaking and processes on cannabis, specifically CBD, and associated proposed safety standards for CBD to be lawfully marketed as a dietary supplement or food additive. Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2024 · first_quarter · RA
Issues related to consumer health care
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2023 · fourth_quarter · Q4
General review and monitoring of legislative and administrative actions related to societal issues or justice; and General health inclusivity issues;
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; and H.R. 3622 Cosmetic Supply Chain Transparency Act. General review and monitoring of Modernization of Cosmetics Regulation Act of 2022 implementation. Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General review of federal policies applying towards paid family and medical leave.
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2023 · third_quarter · Q3
General review and monitoring of renewable energy legislation and regulations.
General international trade policy related to tariffs, import, export concerns. General monitoring of legislative and administrative action related to foreign regulation of chemicals, ingredients, and health care products. General monitoring of legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA) WTO Covid TRIPS waiver proposal General review and monitoring of supply chain concerns, including impact of Russian invasion of Ukraine.
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2023 · second_quarter · Q2
General monitoring of legislative and administrative action related to intellectual property protection.
Multivitamin and nutrition issues. Review of legislative or administrative action related to melatonin, specifically gummy products on products labeled for adult use; and S Res 35 Resolution designating October 22 through October 28, 2023, as "Natural Product Industry Week"
Implementation of H.R. 5376, Inflation Reduction Act of 2022; FY 2024 Appropriations for NIH, NCI, CDC, FDA, and related preventive healthcare accounts; FY2024 Labor, Health and Human Services, Education and Related Agencies (LHHS-ED) Appropriations; H.R.4394 - Energy and Water Development and Related Agencies Appropriations Act, 2024; H.R.4368 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024; and H.R. 4365 Department of Defense Appropriations Act, 2024
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2023 · first_quarter · Q1
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders.
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2022 · fourth_quarter · Q4
S. 923, RECYCLE Act of 2021; General monitoring of legislative and administrative action related to climate change.
Multivitamin and nutrition issues.
H.R. 6207/S. 3357, Humane Cosmetics Act
HALEON US HOLDINGS LLC via HALEON US HOLDINGS LLC
2022 · fourth_quarter · RR
Issues related to consumer health care
General review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers.
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities.
General monitoring of issues and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of issues and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings.
General review and monitoring of renewable energy issues and regulations.
General review and monitoring of U.S. diplomatic relations.
Review and monitoring of Congressional appropriations-specifically on report language related to FSA/HSA eligibility of specialty toothpastes/rinses and dietary supplements
General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility; General monitoring of Medicare coverage of dental services; and General review of issues and rulemaking impacting dual eligible enrollees.
General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; Continued monitor and review of fiscal year (FY) 2025 budget resolution in both House and Senate, along with associated reconciliation instructions; Monitor and review of proposals impacting BEAT, Research and Development expenses; General review and monitoring of proposals in One Big Beautiful Bill Act (OBBBA)
Monitor and review of issues related to the Section 301 tariffs; Monitor and review of issues related to the Section 232 tariffs; Monitor and review of issues related to reciprocal tariffs under International Economic Emergency Powers Act; General monitoring and review of legislative and executive actions on international trade policy related to tariffs, import/export concerns; General monitoring of legislative and administrative action related to review of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
General monitoring and review of issues and executive actions related to or impacting multivitamins and nutrition.
General review of issues and administration action related to pediatric over-the-counter medication concerns.
General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; General monitor and review of issues and administrative action related to domestic supply chain and manufacturing capabilities.
General review and monitoring of nutrition and dietary supplement trends with the U.S. military.
General monitoring of issues and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of issues and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings.
General review and monitoring of renewable energy issues and regulations.
General review and monitoring of U.S. diplomatic relations.
General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process
General review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers.
General review and monitoring of legislative and regulatory proposals impacting Infrastructure Investment and Jobs Act (P.L. 117-58), and the Inflation Reduction Act of 2022 (P.L. 117-169); and Review and monitoring of Congressional appropriations-specifically on report language related to FSA/HSA eligibility of specialty toothpastes/rinses and dietary supplements
General review and monitoring of issues and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information.
General monitoring of issues and administrative action related to intellectual property protection.
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage, General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Review of issues impacting the Dietary Supplement Health and Education Act of 1994; General review of issues and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility; General monitoring of Medicare coverage of dental services; and General review of issues and rulemaking impacting dual eligible enrollees.
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of issues related to federal tax amortization of research and development expenses; General review and monitoring of issues that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of issues and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; Continued monitor and review of fiscal year (FY) 2025 budget resolution in both House and Senate, along with associated reconciliation instructions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
General review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers
H.R. 6284 Improving Measurements for Loneliness and Isolation Act General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General health inclusivity issues
Multivitamin and nutrition issues; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP);
General international trade policy related to tariffs, import, export concerns; General monitoring of legislative and administrative action related to foreign regulation of chemicals, ingredients, and health care products; General monitoring of legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility. General monitoring of Medicare coverage of dental services; General review of legislation, rulemaking impacting dual eligible enrollees
General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings; and
General review and monitoring of legislative and regulatory proposals impacting Infrastructure Investment and Jobs Act (P.L. 117-58), and the Inflation Reduction Act of 2022 (P.L. 117-169); and Review and monitoring of Congressional appropriations-specifically on report language related to FSA/HSA eligibility of specialty toothpastes/rinses, dietary supplements, and Additional Condition for Nonprescription Use (ACNU).
General review and monitoring of nutrition and dietary supplement trends with U.S. military.
General monitoring of legislative and administrative action related to health care policy; including the OTC Monograph Drug User Fee Program (OMUFA). General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; Legislative and administrative action related to pseudoephedrine regulation; General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); H.R. 831 Medicare Medically Necessary Dental Care Act of 2023; H.R. 994/S. 403 Oral Health Literacy Awareness Act; S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information.
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
General review and monitoring of renewable energy legislation and regulations.
General review and monitoring of U.S. diplomatic relations.
General review and monitoring of farm bill legislation, particularly provisions related to nutrition; General review and monitoring of legislative and administrative action related to White House Conference on Hunger
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General monitoring of legislative and administrative action related to climate change; and General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings; and
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
General monitoring of legislative and administrative action related to intellectual property protection.
General review and monitoring of farm bill legislation, particularly provisions related to nutrition; General review and monitoring of legislative and administrative action related to White House Conference on Hunger; and H.R.3087 - Training and Nutrition Stability
General review and monitoring of legislative and administrative actions related to societal issues or justice; and General health inclusivity issues
General international trade policy related to tariffs, import, export concerns; General monitoring of legislative and administrative action related to foreign regulation of chemicals, ingredients, and health care products; General monitoring of legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare and protection of personally identifiable information.
General review and monitoring of U.S. diplomatic relations.
General review of federal policies applying towards paid family and medical leave.
General review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
Multivitamin and nutrition issues; Review of legislative or administrative action related to melatonin, specifically gummy products on products labeled for adult use; and General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP);
General review and monitoring of renewable energy legislation and regulations.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility. General monitoring of Medicare coverage of dental services; General review of legislation, rulemaking impacting dual eligible enrollees
H.R. 6284 Improving Measurements for Loneliness and Isolation Act General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.
General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; and Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General review and monitoring of legislative and regulatory proposals impacting Infrastructure Investment and Jobs Act (P.L. 117-58), and the Inflation Reduction Act of 2022 (P.L. 117-169); and Review and monitoring of Congressional appropriations-specifically on report language related to FSA/HSA eligibility of specialty toothpastes/rinses, dietary supplements, and Additional Condition for Nonprescription Use (ACNU).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility. General monitoring of Medicare coverage of dental services; General review of legislation, rulemaking impacting dual eligible enrollees
General international trade policy related to tariffs, import, export concerns; General monitoring of legislative and administrative action related to foreign regulation of chemicals, ingredients, and health care products; General monitoring of legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
General review and monitoring of legislative and administrative actions related to societal issues or justice; and General health inclusivity issues
General review and monitoring of U.S. diplomatic relations.
Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General review and monitoring of farm bill legislation, particularly provisions related to nutrition; General review and monitoring of legislative and administrative action related to White House Conference on Hunger; and H.R.3087 - Training and Nutrition Stability
General review and monitoring of legislative and regulatory proposals impacting Infrastructure Investment and Jobs Act (P.L. 117-58), and the Inflation Reduction Act of 2022 (P.L. 117-169); and Review and monitoring of Congressional appropriations-specifically on report language related to FSA/HSA eligibility of specialty toothpastes/rinses, dietary supplements, and Additional Condition for Nonprescription Use (ACNU).
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
General monitoring of legislative and administrative action related to intellectual property protection.
General monitoring of legislative and administrative action related to climate change; and General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings; and H.R. 2964/S.1350 Wastewater Infrastructure Pollution Prevention and Environmental Safety Act/WIPPES Act
General review and monitoring of renewable energy legislation and regulations.
Preventing youth consumption of tobacco products; Smoking cessation and over-the-counter alternatives for adult consumers; and General review of legislation and administrative action allowing for original Medicare and Part D coverage of over-the-counter smoking cessation products.
General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; and Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General review and monitoring of legislative and administrative actions on banning noncompete clauses; General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare and protection of personally identifiable information.
Multivitamin and nutrition issues; Review of legislative or administrative action related to melatonin, specifically gummy products on products labeled for adult use
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
General review and monitoring of legislative and administrative actions related to societal issues or justice; and General health inclusivity issues
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General review and monitoring of legislative and administrative actions on banning noncompete clauses; General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare and protection of personally identifiable information.
General review and monitoring of legislative and regulatory proposals impacting Infrastructure Investment and Jobs Act (P.L. 117-58), and the Inflation Reduction Act of 2022 (P.L. 117-169)
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
General review of federal policies applying towards paid family and medical leave.
General monitoring of legislative and administrative action related to intellectual property protection.
H.R. 6284 Improving Measurements for Loneliness and Isolation Act General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.
General review and monitoring of U.S. diplomatic relations.
General international trade policy related to tariffs, import, export concerns. General monitoring of legislative and administrative action related to foreign regulation of chemicals, ingredients, and health care products. General monitoring of legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA) General review and monitoring of supply chain concerns, including impact of Russian invasion of Ukraine.
General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; and Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
Preventing youth consumption of tobacco products; Smoking cessation and over-the-counter alternatives for adult consumers; and General review of legislation and administrative action allowing for original Medicare and Part D coverage of over-the-counter smoking cessation products.
General review and monitoring of nutrition and dietary supplement trends with U.S. military.
General monitoring of legislative and administrative action related to climate change; and General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings; and H.R. 2964/S.1350 Wastewater Infrastructure Pollution Prevention and Environmental Safety Act/WIPPES Act
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
General review and monitoring of farm bill legislation, particularly provisions related to nutrition; General review and monitoring of legislative and administrative action related to White House Conference on Hunger; H.R.3087 - Training and Nutrition Stability; and General review and monitoring legislative actions related to the Farm Bill.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility. General monitoring of Medicare coverage of dental services; General review of legislation, rulemaking impacting dual eligible enrollees
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), Treasury, Dept of
General review and monitoring of U.S. diplomatic relations.
General review and monitoring of renewable energy legislation and regulations.
General review and monitoring of legislative and administrative actions on banning noncompete clauses; Modernization of Cosmetics Regulation Act of 2022 (MoCRA) implementation; and General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare and protection of personally identifiable information.
General review of FDA rulemaking and processes on cannabis, specifically CBD, and associated proposed safety standards for CBD to be lawfully marketed as a dietary supplement or food additive. Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
Multivitamin and nutrition issues. Review of legislative or administrative action related to melatonin, specifically gummy products on products labeled for adult use; and S Res 35 Resolution designating October 22 through October 28, 2023, as "Natural Product Industry Week"
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility. General monitoring of Medicare coverage of dental services; General review of legislation, rulemaking impacting dual eligible enrollees
General review and monitoring of farm bill legislation, particularly provisions related to nutrition. Monitor on legislative and administrative action related to White House Conference on Hunger; H.R.3087 - Training and Nutrition Stability; S.2131 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
General international trade policy related to tariffs, import, export concerns. General monitoring of legislative and administrative action related to foreign regulation of chemicals, ingredients, and health care products. General monitoring of legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA) General review and monitoring of supply chain concerns, including impact of Russian invasion of Ukraine.
General monitoring of legislative and administrative action related to climate change; and General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings; and H.R. 2964/S.1350 Wastewater Infrastructure Pollution Prevention and Environmental Safety Act/WIPPES Act
General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; and Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
H.R. 2670 National Defense Authorization Act for Fiscal Year 2024 S.2587 - Department of Defense Appropriations Act, 2024 H.R.4365 - Department of Defense Appropriations Act, 2024 General review and monitoring of nutrition and dietary supplement trends with U.S. military.
H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act
General monitoring of legislative and administrative action related to intellectual property protection.
H.R.5399 Humane Cosmetics Act of 2023
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023)
Preventing youth consumption of tobacco products; Smoking cessation and over-the-counter alternatives for adult consumers; and General review of legislation and administrative action allowing for original Medicare and Part D coverage of over-the-counter smoking cessation products.
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options.
H.R. 6284 Improving Measurements for Loneliness and Isolation Act General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.
Implementation of H.R. 5376, Inflation Reduction Act of 2022; FY 2024 Appropriations for NIH, NCI, CDC, FDA, and related preventive healthcare accounts; FY2024 Labor, Health and Human Services, Education and Related Agencies (LHHS-ED) Appropriations; H.R.4394 - Energy and Water Development and Related Agencies Appropriations Act, 2024; H.R.4368 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024; and H.R. 4365 Department of Defense Appropriations Act, 2024 S.2131 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 S.2624 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S.2443 - Energy and Water Development and Related Agencies Appropriations Act, 2024
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
General review and monitoring of legislative and administrative actions related to societal issues or justice; and General health inclusivity issues;
H.R. 2670 National Defense Authorization Act for Fiscal Year 2024 S.2587 - Department of Defense Appropriations Act, 2024 H.R.4365 - Department of Defense Appropriations Act, 2024
Implementation of H.R. 5376, Inflation Reduction Act of 2022; FY 2024 Appropriations for NIH, NCI, CDC, FDA, and related preventive healthcare accounts; FY2024 Labor, Health and Human Services, Education and Related Agencies (LHHS-ED) Appropriations; H.R.4394 - Energy and Water Development and Related Agencies Appropriations Act, 2024; H.R.4368 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024; and H.R. 4365 Department of Defense Appropriations Act, 2024 S.2131 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 S.2624 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S.2443 - Energy and Water Development and Related Agencies Appropriations Act, 2024
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; and H.R. 3622 Cosmetic Supply Chain Transparency Act. General review and monitoring of Modernization of Cosmetics Regulation Act of 2022 implementation. Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General monitoring of legislative and administrative action related to intellectual property protection.
General review of federal policies applying towards paid family and medical leave.
General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process; and Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility. General monitoring of Medicare coverage of dental services; General review of legislation, rulemaking impacting dual eligible enrollees
Preventing youth consumption of tobacco products; Smoking cessation and over-the-counter alternatives for adult consumers; and General review of legislation and administrative action allowing for original Medicare and Part D coverage of over-the-counter smoking cessation products.
Multivitamin and nutrition issues. Review of legislative or administrative action related to melatonin, specifically gummy products on products labeled for adult use; and S Res 35 Resolution designating October 22 through October 28, 2023, as "Natural Product Industry Week"
General review and monitoring of legislative and administrative actions on banning noncompete clauses; Modernization of Cosmetics Regulation Act of 2022 (MoCRA) implementation; and General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare and protection of personally identifiable information.
General review and monitoring of farm bill legislation, particularly provisions related to nutrition. Monitor on legislative and administrative action related to White House Conference on Hunger; H.R.3087 - Training and Nutrition Stability; S.2131 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
General review and monitoring of U.S. diplomatic relations.
General review of FDA rulemaking and processes on cannabis, specifically CBD, and associated proposed safety standards for CBD to be lawfully marketed as a dietary supplement or food additive. Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Defense Production Act (DPA) issues, specifically on manufacturing impacts on over-the-counter medications. S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023
General review of federal policies applying towards paid family and medical leave. General review of legislative and administration action related to pediatric over-the-counter concerns.
General monitoring of legislative and administrative action related to climate change; and General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings; and H.R. 2964/S.1350 Wastewater Infrastructure Pollution Prevention and Environmental Safety Act/WIPPES Act
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses
General international trade policy related to tariffs, import, export concerns. General monitoring of legislative and administrative action related to foreign regulation of chemicals, ingredients, and health care products. General monitoring of legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA) WTO Covid TRIPS waiver proposal
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications.
General monitoring of legislative and administrative action related to climate change; and General monitoring of legislative and administrative action related to sustainability, particularly related to packaging.
General review and monitoring of legislative and administrative actions on banning noncompete clauses; and Modernization of Cosmetics Regulation Act of 2022 (MoCRA) implementation.
General review of federal policies applying towards paid family and medical leave.
General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process
General review of federal policies applying towards paid family and medical leave.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility. General monitoring of Medicare coverage of dental services; General review of legislation, rulemaking impacting dual eligible enrollees
General review and monitoring of legislative and administrative actions related to societal issues or justice; and General health inclusivity issues;
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Defense Production Act (DPA) issues, specifically on manufacturing impacts on over-the-counter medications. S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023
General review and monitoring of farm bill legislation, particularly provisions related to nutrition. Monitor on legislative and administrative action related to White House Conference on Hunger; and H.R.3087 - Training and Nutrition Stability.
H.R. 2670 National Defense Authorization Act for Fiscal Year 2024
Preventing youth consumption of tobacco products. Smoking cessation and over-the-counter alternatives for adult consumers.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
General review and monitoring of farm bill legislation, particularly provisions related to nutrition.
General review and monitoring of legislative and administrative actions on banning noncompete clauses.
Multivitamin and nutrition issues.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility. General monitoring of Medicare coverage of dental services; General review of legislation, rulemaking impacting dual eligible enrollees
Implementation of H.R. 5376, Inflation Reduction Act of 2022; FY 2024 Appropriations for NIH, NCI, CDC, FDA, and related preventive healthcare accounts; and FY24 Labor, Health and Human Services, Education and Related Agencies (LHHS-ED) Appropriations
General monitoring of legislative and administrative action related to intellectual property protection.
General review of federal policies applying towards paid family and medical leave.
Preventing youth consumption of tobacco products. Smoking cessation and over-the-counter alternatives for adult consumers.
General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process
General international trade policy related to tariffs, import, export concerns. General monitoring of legislative and administrative action related to foreign regulation of chemicals, ingredients, and health care products. General monitoring of legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA) WTO Covid TRIPS waiver proposal
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications.
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses
General review and monitoring of legislative and administrative actions related to societal issues or justice; and General health inclusivity issues;
General review of federal policies applying towards paid family and medical leave.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; H.R. 5376, Inflation Reduction Act of 2022; H.R. 6833, Making continuing appropriations for fiscal year 2023, and for other purposes.
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility.
General review and monitoring of legislative and administrative actions related to societal issues or justice; General health inclusivity issues; H.R. 5, Equality Act; H.R. 8404, Respect for Marriage Act.
H.R. 5376, Build Back Better Act; H.R.5747 - To amend the Internal Revenue Code of 1986 to include certain over-the-counter dietary supplement products as qualified medical expenses; H.R.6271 - Health Savings Act of 2021
S.888/H.R 2116, Creating a Respectful and Open World for Natural (CROWN) Hair Act of 2021
General monitoring of legislative and administrative action related to intellectual property protection.
S. 936/H.R. 5502, Integrity, Notification, and Fairness in Online Retail Marketplaces (INFORM) for Consumers Act; S. 1843/H.R. 3429, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act; S. 2047/H.R. 3990, No PFAS in Cosmetics Act;
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA) S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act H.R. 7667 Food and Drug Amendments of 2022
General international trade policy related to tariffs, import, export concerns. S. 1260/H.R. 4521, United States Innovation and Competition Act of 2021 General monitoring of legislative and administrative action related to foreign regulation of chemicals, ingredients, and health care products. General monitoring of legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE